NCT05625737 2024-09-19
Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
Clinical Trials
1,024 trialsNCT04159974 2024-05-09
RICE
University of Cologne
Phase 2 Unknown
NCT06405685 2024-05-08
Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT06345300 2024-04-03
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT06231680 2024-03-29
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Phase 2 Unknown
NCT06322563 2024-03-21
Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04062656 2024-03-12
IMAGINE
University Hospital, Essen
Phase 2 Unknown
NCT06301828 2024-03-08
Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors
Nanjing First Hospital, Nanjing Medical University
Phase 2 Unknown
NCT06280690 2024-02-29
SGM-T1
Leiden University Medical Center
Phase 2 Unknown
NCT06284746 2024-02-29
Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer
Chinese PLA General Hospital
Phase 2 Unknown
NCT05184803 2024-02-28
A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer
Asan Medical Center
Phase 2 Unknown
NCT05122091 2024-02-26
Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma
Guangxi Medical University
Phase 2 Unknown
NCT05371223 2024-02-26
Nab-PIPAC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT05178043 2024-02-22
GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
Suzhou Kintor Pharmaceutical Inc,
Phase 2 Unknown
NCT04096417 2024-02-21
Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Academic and Community Cancer Research United
Phase 2 Unknown
NCT06210334 2024-02-20
HAI-TL
Eastern Hepatobiliary Surgery Hospital
Phase 2 Unknown
NCT03924466 2024-02-16
VUBAR
Universitair Ziekenhuis Brussel
Phase 2 Unknown
NCT06262581 2024-02-16
Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery
Sun Yat-sen University
Phase 2 Unknown
NCT05029102 2024-02-12
TAS-102 and Anlotinib in ≥3 Lines mGC
Zhejiang University
Phase 2 Unknown
NCT04844385 2024-02-09
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT06250894 2024-02-09
Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT05980689 2024-02-07
Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05933980 2024-02-06
REGOTORICOX
Sun Yat-sen University
Phase 2 Unknown
NCT06239870 2024-02-02
ESTIMATE
Yunnan Cancer Hospital
Phase 2 Unknown
NCT05291156 2024-02-01
CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
University of Campania Luigi Vanvitelli
Phase 2 Unknown
NCT03503630 2024-01-31
Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma
American University of Beirut Medical Center
Phase 2 Unknown
NCT06233981 2024-01-31
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT06231017 2024-01-30
Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT06227325 2024-01-26
Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression
Henan Cancer Hospital
Phase 2 Unknown
NCT06202014 2024-01-19
Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05435313 2024-01-17
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
Fudan University
Phase 2 Unknown
NCT05962450 2024-01-16
Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
Beijing YouAn Hospital
Phase 2 Unknown
NCT06198465 2024-01-10
Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma
Xijing Hospital
Phase 2 Unknown
NCT06192784 2024-01-09
CCGLC-012
Tongji Hospital
Phase 2 Unknown
NCT06197438 2024-01-09
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT02037048 2024-01-08
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Phase 2 Unknown
NCT05626569 2024-01-03
Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC
Sun Yat-sen University
Phase 2 Unknown
NCT01541709 2024-01-02
Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
Asan Medical Center
Phase 2 Unknown
NCT05859477 2024-01-02
NIVOFGFR2
Kidney Cancer Research Bureau
Phase 2 Unknown
NCT04329429 2023-12-20
A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer
RemeGen Co., Ltd.
Phase 2 Unknown
NCT05578287 2023-12-07
DETECT
Sun Yat-sen University
Phase 2 Unknown
NCT06153368 2023-12-07
Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05820906 2023-12-06
Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03729687 2023-11-30
LARCT-US
Uppsala University
Phase 2 Unknown
NCT05262335 2023-11-28
ALTER-G-001
Ruijin Hospital
Phase 2 Unknown
NCT05709171 2023-11-22
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
Rigshospitalet, Denmark
Phase 2 Unknown
NCT05512520 2023-11-18
EC-CRT-003
Sun Yat-sen University
Phase 2 Unknown
NCT06134193 2023-11-18
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT06134765 2023-11-18
Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04999332 2023-11-15
LOTS
National Cheng-Kung University Hospital
Phase 2 Unknown